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Focal adhesion kinase (FAK) is a non-receptor tyro-
sine kinase that is regulated by integrins. Upon activa-
tion, FAK generates signals that modulate crucial cell
functions, including cell proliferation, migration, and
survival. The C-terminal focal adhesion targeting (FAT)
sequence mediates localization of FAK to discrete re-
gions in the cell called focal adhesions. Several binding
partners for the FAT domain of FAK have been identi-
fied, including paxillin. We have determined the solu-
tion structure of the avian FAT domain in complex with
a peptide mimicking the LD2 motif of paxillin by NMR
spectroscopy. The FAT domain retains a similar fold to
that found in the unliganded form when complexed to
the paxillin-derived LD2 peptide, an antiparallel four-
helix bundle. However, noticeable conformational
changes were observed upon the LD2 peptide binding,
especially the position of helix 4. Multiple lines of evi-
dence, including the results obtained from isothermal
titration calorimetry, intermolecular nuclear Over-
hauser effects, mutagenesis, and protection from para-
magnetic line broadening, support the existence of two
distinct paxillin-binding sites on the opposite faces of
the FAT domain. The structure of the FAT domain-LD2
complex was modeled using the program HADDOCK
based on our solution structure of the LD2-bound FAT
domain and mutagenesis data. Our model of the FAT
domain-LD2 complex provides insight into the molecu-
lar basis of FAK-paxillin binding interactions, which
will aid in understanding the role of paxillin in FAK
targeting and signaling.
Focal adhesion kinase (FAK),1 is an essential protein tyro-
sine kinase as fak/ mice exhibit embryonic lethality (1). FAK
signaling is regulated by the interactions of transmembrane
receptors, integrins, with their extracellular matrix ligands
(2–4). Integrin signaling via FAK controls several critical bio-
logical processes including cell spreading, cell migration, and
cell survival. In addition to its role in the control of these
functions in normal cells, FAK may also function in the pathol-
ogy of human disease, e.g. cancer (5–10). FAK is overexpressed
in a number of tumors, including cancers of the breast and
prostate. Furthermore, experimental overexpression of FAK
can promote some phenotypes of cancer cells, including growth
in soft agar and invasion (11–14). Attenuation of endogenous
FAK signaling in some cancer cells can impair anchorage-
independent growth, motility, and invasion (15–18). These in-
vestigations demonstrate that FAK is fundamentally impor-
tant in normal development and that aberrant FAK signaling
may contribute to carcinogenesis.
FAK discretely co-localizes with integrins at focal adhesions,
sites of close contact with the extracellular matrix (2, 3). The
sequences within FAK responsible for localization have been
mapped to 140 residues near the C terminus, a region defined
as the focal adhesion targeting (FAT) sequence or domain (19,
20). Two focal adhesion-associated proteins interact with FAK
via the FAT domain, paxillin and talin (19, 21, 22). The precise
mechanism of focal adhesion targeting has not been elucidated.
Evidence both for and against paxillin and talin as the sole
mediators of FAK localization has been presented in the liter-
ature (19, 21, 23–25). This discrepancy may be resolved by
postulating multiple mechanisms for localization, i.e. a paxillin-
dependent and a talin-dependent mechanism. Proper subcellu-
lar localization of FAK is essential for integrin-dependent reg-
ulation and for transmission of downstream signals (24, 26).
Furthermore, the C-terminal domain of FAK has been used as
a potent dominant negative mutant to inhibit signaling via
endogenous FAK (27). Thus, this region of FAK is important for
biochemical and biological signaling and is potentially a target
for therapeutic intervention.
Paxillin is also an essential protein as the paxillin/ mice
are embryonically lethal (28). Paxillin has been implicated in
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controlling a subset of the biological processes under the
control of FAK, including cell spreading and cell migration
(28, 29). In several different scenarios, paxillin has been
implicated in the control of motility. The 41 integrin pro-
motes cell motility, and paxillin was identified as a direct
binding partner of the cytoplasmic tail of the 4 subunit (30).
A mutant of 4 that is defective for paxillin binding fails to
promote cell motility. This interaction is also required for
41-dependent tyrosine phosphorylation of FAK and Pyk2,
and these two tyrosine kinases were implicated in regulating
motility downstream of 41 (30, 31). Tyrosine phosphoryla-
tion of paxillin may play a role in regulating cell motility. A
mutant of paxillin completely defective for tyrosine phospho-
rylation functions as a dominant negative mutant and in one
system promotes motility, whereas in a second system it
inhibits motility (32, 33). Although the discrepancy between
these studies remains to be completely resolved, the evidence
supports a role for tyrosine phosphorylation in the regulation
of motility by paxillin. FAK and Pyk2 can regulate tyrosine
phosphorylation of paxillin, directly or indirectly. Further-
more, the association of FAK with paxillin may be a mecha-
nism to promote maximal phosphorylation of paxillin (34).
These findings demonstrate the important interplay between
FAK/Pyk2 and paxillin that appears to control tyrosine phos-
phorylation and the regulation of cell motility.
Paxillin is an adaptor protein with docking sites for a variety
of binding partners (35). The C-terminal half of paxillin con-
tains four LIM domains, which are domains that function in
mediating protein-protein interactions. The third LIM domain
is vital for paxillin function as it contains the major focal
adhesion localization determinant within the molecule (36).
The binding partner promoting localization has not been iden-
tified. The N-terminal half of paxillin contains sites of tyrosine
phosphorylation and five copies of a leucine-rich peptide motif
called the LD motif, with a consensus sequence LDXLLXXL
(35, 37). This peptide sequence also functions in mediating
protein-protein interactions. Many paxillin-binding partners
associate via these LD motifs including FAK, vinculin, PKL,
actopaxin, ILK, and the E6 oncoprotein of papillomavirus (35,
37). The binding of FAK to paxillin is mediated by two LD
motifs, called LD2 and LD4 (36). Although LD motif-mediated
interactions appear important for the function of paxillin, nei-
ther the molecular and structural basis for these interactions
nor the binding specificity have been elucidated.
Recent structural analysis of the FAT domain of FAK has
demonstrated that this domain forms an anti-parallel four-
helix bundle (38–40). Two hydrophobic patches on opposite
faces of the FAT domain were initially proposed as docking
sites for LD motifs of paxillin (39). Hydrophobic patch 1 (HP1)
was at the interface of helix 2 and 3, and HP2 was at the
interface of helix 1 and 4. In this model, the LD motifs were
assumed to be -helical in nature, and two LD motifs were
proposed to bind to the FAT domain, one to each hydrophobic
patch (39). In contrast, Arold et al. (38) proposed a single
paxillin-binding site at the interface between helix 2 and 3
(HP1) based upon their crystal structure along with some pre-
viously reported mutagenesis data. A subsequent solution
structure of FAT in complex with an LD motif peptide funda-
mentally contradicted the original model (40). The LD2-dock-
ing site on FAT was identified using a paramagnetically la-
beled peptide, as no interactions could be detected between the
peptide and the FAT domain by NOE-based approaches. Al-
though evidence that the LD motif peptide was -helical in
solution was presented, other aspects of the interaction were
different. Their results indicated that the FAT domain contains
a single LD motif-binding site at HP2 (40). Furthermore, the
peptide docked in the opposite orientation relative to the model
of Hayashi et al. (39), which was based on the crystal structure
of the FAT domain. Although these studies have provided im-
portant insight into the structure of the FAT domain, there are
a number of unresolved issues, including the details of the
interaction with paxillin.
Here we report the solution structure of the avian FAT
domain in complex with a paxillin LD2 peptide solved by NMR
spectroscopy. Our study demonstrates that two sites contain-
ing either HP1 or HP2, which are on the opposite faces of the
FAT domain, function as paxillin LD motif-binding sites with
similar binding affinities, yet the thermodynamic basis for
binding to the two sites is fundamentally different. Our exper-
imentally derived models of FAT domain-LD2 complexes pro-
vide important insight into the structural basis of paxillin
recognition.
EXPERIMENTAL PROCEDURES
Expression and Purification of the FAT of FAK and Peptide Synthe-
sis—The FAT sequence, containing residues 920–1053 of the avian
FAK plus a 12-amino acid N-terminal linker, was expressed and puri-
fied as previously described (34).2 A 27-amino acid residue LD2 peptide
(133MTSTSLGSNLSELDRLLLELNAVQHNP159) was chemically syn-
thesized at the University of North Carolina microprotein sequencing
and peptide synthesis facility. A [15N]leucine-labeled LD2 peptide and a
shorter LD2 peptide lacking 8 N-terminal residues (residues 141–159)
were also synthesized. Protein and peptide concentrations were meas-
ured using the BCA assay (Pierce) because the results lie within 5% of
the determinations by amino acid composition analysis.
Isothermal Titration Calorimetry (ITC)—Protein solutions were dia-
lyzed thoroughly against ITC buffer (50 mM HEPES, 100 mM NaCl, and
2 mM NaN3 at pH 7.0) and degassed prior to ITC measurements. For
experiments at different temperatures, the pH was corrected to ensure
constant pH. Titrations were conducted at the University of North
Carolina Macromolecular Interactions Facility using a Microcal VP-
ITC. The FAT domain or FAT domain variants (50 M) were placed in
the calorimetric cell and titrated with 1 mM LD2 peptide in the ITC
buffer. The heat of association was obtained from the difference be-
tween the integrated heat of reaction and the corresponding heat of
dilution. Data were analyzed using the ITC version of Origin 5.0 with
embedded calorimetric fitting routines, with H (the change in binding
enthalpy, cal/mol) and Ka (the binding constant, M
1) as adjustable
parameters. An ITC study was also conducted on a FAK homolog, Pyk2.
Mapping the Binding Interface from Line Broadening by Gd-EDTA
Paramagnetic Probe—Gd(III)-EDTA, a paramagnetic relaxation broad-
ening reagent, was titrated into samples of uniformly 15N-enriched free
and LD2-bound 15N-enriched FAT domain samples, and the effects of
line broadening were compared as the difference in normalized height
of amide HSQC peaks (42). Two dimensional 1HN-
15N HSQC spectra of
0.2 mM 15N-labeled FAT domain samples, free or in complex with the
LD2 peptide (molar ratio 1:8), were collected in the presence of a range
of concentrations of 1:1 Gd(III)-EDTA (0.6, 1.2, 1.8, 2.4, 3.0, 6.0, and 9.0
mM). Line broadening was measured as a ratio of the height of a
backbone amide peak at a given concentration of Gd(III)-EDTA to the
height in the absence of the paramagnetic probe. Normalized heights of
NH peaks obtained from the HSQC spectrum of the free FAT domain in
the presence of 3 mM Gd(III)-EDTA were subtracted from normalized
heights of NH peaks taken from the HSQC spectrum of the FAT do-
main-LD2 complex in the presence of 3 mM Gd(III)-EDTA.
Interactions with Full-length Paxillin—GST fusion proteins were
induced as described above. After immobilization on glutathione beads,
the fusion proteins were used to test paxillin binding. CE cells were
lysed in Tx-RIPA buffer (50 mM Tris, pH 7.3, 150 mM NaCl, 1% Triton
X-100, 0.5% deoxycholate) (34), and the protein concentration was de-
termined by using the BCA assay. Lysates were pre-cleared with 50 g
of GST per 1 mg of lysate for 1 h at 4 °C. Then 500 g of lysate was
incubated with 6 g of GST fusion proteins for 1 h at 4 °C. The beads
were washed twice with Tx-RIPA and twice with phosphate-buffered
saline, and bound proteins were eluted by boiling in Laemmli’s sample
buffer. The samples were analyzed by Western blotting using a paxillin
monoclonal antibody (BD Transduction Laboratories, Lexington, KY).
2 K. C. Prutzman, G. Gao, M. L. King, V. V. Iyer, G. A. Mueller, M. D.
Schaller, and S. L. Campbell, submitted for publication.
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For expression in 293 cells, wild type FAK and mutants were subcloned
into the pcDNA3 expression vector (Clontech). Cells were transfected
using Lipofectamine according to the manufacturer’s recommendations
(Invitrogen). Seventy two hours post-transfection, cells were lysed in
Tx-RIPA buffer and protein concentrations determined using the BCA
assay. FAK was immunoprecipitated from 1 mg of lysate using the BC4
polyclonal antiserum (26, 43). Immune complexes were washed twice
with Tx-RIPA buffer and twice with phosphate-buffered saline, and
bound proteins were eluted with sample buffer. Bound paxillin was
detected by Western blotting by using a paxillin monoclonal antibody.
The blot was then stripped and re-probed for FAK as a loading control.
NMR Samples—Purified proteins were exchanged into NMR buffer
(20 mM deuterated Tris maleate (Isotec, Miamisburg, OH), 50 mM NaCl,
0.1 mM EDTA, 0.1% NaN3, and 10% D2O, pH 6.0), using centrifugal
filter devices with a 10,000-dalton molecular weight cut-off BioMax
membrane (Millipore, Bedford, MA). Lyophilized LD2 peptide (protein/
peptide molar ratio 1:8) was added into diluted protein solution (1.5
mg/ml). NMR samples of the FAT domain-LD2 complex were then
concentrated to desired concentrations using an Amicon stirred ul-
trafiltration cell (model 8003) equipped with a 1,000-dalton molecular
weight cut-off YM1 ultrafiltration membrane (Millipore, Bedford,
MA). 1 M D-Phe-Pro-Arg-chloromethylketone (Calbiochem) and 0.5
mg/ml pefabloc SC (Roche Applied Science) were used in all NMR
samples to inhibit residual thrombin remaining from GST cleavage
during purification.
NMR Spectroscopy—All NMR experiments were carried out at 310 K.
1H chemical shifts were referenced relative to an external 2,2-dimethyl-
2-silapentane-5-sulfonate sample, whereas 13C and 15N chemical shifts
were referenced indirectly to 2,2-dimethyl-2-silapentane-5-sulfonate as
described (44). Spectra were processed with NMRPipe program version
2.1 (45) and analyzed by NMRView program version 5.0.4 (46). A
three-dimensional simultaneous 13C/15N-edited NOESY spectrum
(75-ms mixing time) was collected on a Varian Inova 800 MHz spec-
trometer (47). To identify intermolecular contacts between the FAT
domain and LD2 peptide, a pair of three-dimensional simultaneous
13C/15N edited NOESY spectra (100 ms mixing time) were also acquired
under identical conditions on a Varian Inova 600 MHz spectrometer,
with or without F1 decoupling during acquisition. All other spectra
were collected on a Varian Inova 600-MHz spectrometer. Backbone
sequential assignments were obtained manually from the following
series of experiments on a 0.6 mM uniformly 13C/15N-labeled FAT pro-
tein with 4.8 mM unlabeled LD2 peptide: two-dimensional 1HN-
15N
TROSY HSQC (see representative spectrum in Supplemental Material
Fig. 1), two-dimensional 1H-13C HSQC, three-dimensional HNCA (48),
three-dimensional HN(CO)CA (49), three-dimensional HNCACB (48,
50), three-dimensional CBCA(CO)NH (51), and three-dimensional
HNCO (52). Two dimensional 1HN-
15N TROSY HSQC spectra were also
collected on a 0.2 mM selectively [15N]Leu-labeled protein in complex
with LD2 peptide, and a 0.2 mM [15N]Lys()-labeled protein in complex
with LD2 peptide (protein/peptide molar ratio 1:8). These two spectra
provided starting points for the assignments. Side chain assignments
were achieved using the following experiments: three-dimensional
HCCH-COSY (53), three-dimensional HCCH-TOCSY (54), three-di-
mensional H(CCO)-TOCSY-NNH, and three-dimensional (H)C(CO)-
TOCSY-NNH (55, 56). Aromatic side chain assignments were obtained
from two-dimensional (H)C(CCC)H and two-dimensional
(H)C(CC)H experiments (57). 1HN-
15N residual dipolar coupling
values were measured using 7.5 mg/ml Pf1 phage as aligning medium
(ASLA Ltd., Riga, Latvia). The protein concentration was 0.25 mM, and
peptide concentration was 2 mM. No significant spectral difference was
observed in two-dimensional 1HN-
15N HSQC spectra with and without
phage. Two dimensional spectra were collected using gNhsqc_IPAP
pulse sequence from ProteinPack (Varian) on the complex samples with
and without Pf1 phage (58).
Structure Calculations—Results of the CSI predictions and the TA-
LOS program were analyzed for identification of secondary structure
elements (59–61). The crystal structure (Protein Data Bank access code
1k40) from Hayashi et al. (39) served as starting structure for calcula-
tions after minor modifications, because of small differences in the
primary sequence between mouse and the avian FAT domain. The
program Insight II (Accelrys, San Diego, CA) was used to append the
12-amino acid residue linker to the N terminus of the avian FAT
domain and to substitute the following amino acid residues: T972S,
I973L, A975V, G996A, S1000N, L1046I, G1047S, and T1049S. Dihedral
angle constraints were derived from the C chemical shifts by using the
program TALOS, which matches sequence and chemical shifts with a
data base of known structures and chemical shifts (61). Using the
criteria of TALOS program, only “good” matches of dihedral angles were
used for restraints, and errors were set as 2 or at least 20°. The
hydrogen bonds were assigned based on manually assigned NOEs and
the secondary structure predictions by TALOS. In total, 212 hydrogen
bond and 92 dihedral angle constraints were used in structure calcula-
tions. RDC values (5.9 to 9 Hz) were fit to our preliminary NMR
structure of the FAT domain-LD2 complex using the RDCA program
(62), and a rhombicity value of 0.5075 was obtained. Uncertainties of
1DNH RDC were estimated to be 1.5 Hz.
The program CNS version 1.1 with ARIA version 1.2 module was
used to calculate the structures of the avian FAT domain as described
below (63–66). The structural restraints included NOE, hydrogen bond,
dihedral angle, and RDC restraints. The NOE distance restraints were
derived from a three-dimensional simultaneous 13C/15N-edited NOESY
peak lists with 75-ms mixing time. The peak lists were generated
automatically by NMRView and edited manually to remove any obvious
water and apodization artifacts. The peak lists were unassigned and
uncalibrated with respect to distance. To calibrate the NOE distances,
the rotational correlation time of the complex, c, was set to 10 ns and
was based on c values obtained on proteins of this size at similar
temperature. The default parameters for ARIA produced structures
with poor convergence. Several parameters were optimized, including
the ambiguous cut-off (	), the violation tolerance (vtol), and maximum
number of ambiguities per peak (nmax), to provide better noise discrim-
ination. The following scheme led to the best convergence over nine
iterations: 	  (0.95, 0.95, 0.95, 0.94, 0.93, 0.92, 0.91, 0.90, and 0.80),
vtol  (5.0, 2.0, 1.0, 0.5, 0.25, 1.0, 0.1, 0.1, and 0.1), nmax  5 for all
iterations. An ensemble of 25 calculated NMR structures of the avian
FAT domain was selected for further analysis.
Docking Protocol—Model 3 from the family of 25 accepted structures
of the FAT domain in the LD2 peptide bound state was selected as a
representative set of coordinates. The flexible N-terminal 12-residue
linker was removed. The structured region of LD2 peptide (138LG-
SNLSELDRLLLEL152) in the FAT domain-LD2 complex was deter-
mined from the analysis of a two-dimensional 1HN-
15N HSQC spectrum
of a complex of unlabeled FAT domain and selectively [15N]leucine-
labeled LD2 peptide (see HSQC spectra in Supplemental Material Fig.
2). Upon binding, the amide peaks of 6 of 7 leucine residues were clearly
broadened. We assume the amide peak at 8.3 and 120.4 ppm, which are
the narrowest and most intense leucine NH peaks that do not shift in
the spectra of both free and bound states, correspond to leucine residues
at the ends of the peptide sequence. Furthermore, consistent with the
assumptions made in the previous studies (39, 40), we assume the
peptide residues 138–152 adopt a helical conformation when complexed
to FAT given its strong propensity to form -helix (39, 40). The initial
peptide coordinates were generated in the Discover module of the In-
sight II program using standard helical conformation, followed by 1,000
steps of molecular dynamics and 3,000 steps of energy minimization in
the CHARM force field. The docking process was carried out using the
HADDOCK (high ambiguity driven docking) program (67). Docking of
the LD2 peptide onto helix 1, 4 (HP2) and helix 2, 3 (HP1) sites of the
FAT domain were conducted separately. The side chains of the LD2
peptide were allowed to move to allow for conformational rearrange-
ments. Because both chemical shift perturbation and paramagnetic
probe mapping were not able to define precisely the interaction sites,
only mutagenesis data were used to drive the docking process. Accord-
ing to established criteria of the HADDOCK program, the “active”
residues are those that have been shown by mutations to abolish or
significantly perturb complex formation and are solvent-exposed. The
passive residues correspond to the residues that are surface neighbors
of the active residues and also have a high solvent accessibility (67).
FAT residue Ile-937 in helix 1, Glu-949, Lys-956, and Arg-963 in helix
2, Asn-992 and Lys-1003 in helix 3 (24, 39), and Lys-1019, His-1026,
and Lys-1033 in helix 4 are therefore considered to be active residues
according to our ITC results and previous mutagenesis studies. For the
LD2 peptide, only the critical Asp-146 residue is identified as an active
residue. Four neighboring LD2 residues, Leu-142, Ser-143, Leu-149,
and Leu-150, are considered to be passive residues. Relative solvent
accessibility of all these residues is larger than 70% as calculated with
NACCESS (68). The default HADDOCK parameters were used except
only 200 initial complex structures were generated, and the best 25
solutions in terms of intermolecular energies were then refined in water
(default values were 1,500 and 200, respectively) (67).
RESULTS AND DISCUSSION
Characterization of FAT Domain Binding to LD2 Peptide by
ITC—To characterize the association of paxillin with FAK, the
interaction of synthetic peptides mimicking the LD2 motif of
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paxillin with the purified FAT domain of FAK was examined




 H  TS (Eq. 1)
Representative titrations are shown in Fig. 1A, and the ther-
modynamic parameters of binding are listed in Table I. The
experimental data best fit a two-site model for the wild type
FAT domain, with fixed stoichiometry (n) of 1 for both sites in
order to more accurately fit Ka and H by decreasing the
number of variables. The 2 value for the goodness of fit of the
data to the two-site binding model was 536, compared with 105
if the data were fit to a one-site model. The ITC results also
demonstrate that the two sites are energetically different, i.e.
FIG. 1. A, calorimetric titrations of wild type FAT, single mutant I937A (helix 1), and triple mutant E949A/K956A/R963A (helix 2) with LD2
peptide in HEPES buffer at pH 7.0, 299 K. Top panels show raw data with integration base line (red). Bottom panels show data after peak
integration, subtraction of blank titrations, and concentration normalization. The red solid lines in the bottom panels represent the fit to a two
binding site model for wild type FAT and a single binding site model for I937A and EKR mutant, respectively. Thermodynamic parameters are
summarized in Table I. B, LD2 peptide contact sites of FAT were mapped by paramagnetic relaxation broadening (see “Experimental Procedures”
for details). Amide protons experiencing protection from 3.0 mM Gd(III)-EDTA are drawn as colored balls in the presence of LD2 peptide (green)
and a shorter LD2 peptide lacking N-terminal 8 residues (gold). Amide protons protected with both peptides are shown as red balls. C,
two-dimensional 1H-1H planes taken from a pair of three-dimensional simultaneous 13C/15N edited NOESY spectra with and without F1 decoupling
during acquisition. Intermolecular NOEs between labeled FAT and unlabeled LD2 peptide are singlets in both spectra, whereas intramolecular
NOEs for labeled FAT are doublets in the coupled spectrum. The boxed peaks correspond to intermolecular NOEs between the amide protons of
residue His-1026 (helix 4) and Lys-989 (helix 3) to the peptide, respectively.
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one being largely enthalpically driven and the other mainly
entropically driven. Both sites have binding affinities of 10
M. However, it is important to point out that usually in
multiparameter fitting there could be strong correlations be-
tween certain variables that are being determined, which can
introduce substantial uncertainties in the actual values. So
the real uncertainties of the thermodynamic parameters
should be much larger than the error ranges given in Table I.
Nevertheless, the ITC data from the two FAT mutants as
discussed below strongly support the interpretation of the
presence of two energetically distinct LD2-binding sites within
the FAT domain. ITC studies were also performed at 308 K.
The change in heat capacity of binding (Cp) was determined
using Equation 2.
Cp 
 HT2  HT1/T2  T1 (Eq. 2)
The heat capacity of binding, Cp, was estimated to be 0.3
kcalmol1K1 and 0.4 kcalmol1K1 for the two binding
sites. The large negative values of Cp indicate significant
hydrophobic interactions are involved in binding of the LD2
peptide at both binding sites. Interestingly, the close family
member of FAK, Pyk2, possesses very similar thermodynamic
characteristics of LD2 binding to that of the FAT domain (Table
I). Pyk2 and FAK share a similar structural organization with
a tyrosine kinase domain flanked by noncatalytic domains at
both N and C termini. Moreover, the FAT domain and the
C-terminal domain of Pyk2 share 60% sequence identity, and
constitutive association of Pyk2 with paxillin has been demon-
strated (69–71). Our ITC results support the hypothesis that
the C-terminal domain of Pyk2 and the FAT domain are struc-
turally related and may share similar global folding and pax-
illin binding properties.
A number of previously characterized mutants of the FAT
domain have been examined for paxillin binding. These include
I937E and I999E, which contain substitutions for conserved
hydrophobic residues in helix 1 and 3, respectively, and E949A/
K956A/R963A and H1026A/K1033A, each containing substitu-
tions for two conserved positively charged residues (Lys-956
and Arg-963) in helix 2 and 4, respectively. These mutants
were capable of binding paxillin in vitro, albeit qualitatively
less well than wild type FAK (24, 39). For ITC characterization,
these mutations were engineered into the GST-FAT sequence
construct, with the exception that alanine substitutions were
made for Ile-937 and Ile-999, instead of the more dramatic
glutamic acid substitution. Each mutant was expressed, puri-
fied, and analyzed for LD2 peptide binding by ITC (Fig. 1A). In
contrast to the data for the wild type FAT domain (Fig. 1A, left
panel), the I937A mutant data fit well only to a one binding site
model. From the thermodynamic parameters shown in Table I,
it is obvious that I937A mutation abolishes the LD2 binding
activity of the helix 1, 4 site and has little effect on the helix 2,
3 binding site. The I999A mutant exhibited LD2 binding activ-
ity similar to wild type FAT (data not shown). The ITC binding
data for the E949A/K956A/R963A mutant also fits well only to
a one binding site model. This mutation disrupts the LD2
binding activity of helix 2, 3 site, leaving the helix 1, 4 site
almost intact. In contrast, the H1026A/K1033A mutant de-
creases the LD2 binding affinity of the helix 1, 4 site by just
2-fold. A second mutation, K1019A/H1026A/K1033A, has a sig-
nificant effect on the binding affinity of the helix 1, 4 site and
decreases the binding affinity of this site by 10-fold (data not
shown).
Mapping the Paxillin-binding Sites on FAT Using Gadolini-
um(III)-EDTA as a Paramagnetic Line Broadening Reagent—
Attempts to identify the interaction sites of the LD2 peptide
within the FAT domain by chemical shift mapping failed be-
cause addition of the peptide induced dramatic chemical shift
changes for the majority of the residues of the FAT domain,
consistent with previous observations (40). As an alternative
strategy, Gd(III)-EDTA was used as a paramagnetic probe to
map the binding interface (42). Relative amide peak heights
were estimated as a ratio of the height of a particular peak in
the two-dimensional 1HN-
15N HSQC spectrum with paramag-
netic probe present to the HN peak height with no paramag-
netic probe present. In particular, relative heights for the free
FAT domain with 3 mM Gd(III)-EDTA present were subtracted
from relative heights for the FAT domain bound to LD2 with 3
mM Gd(III)-EDTA present. The threshold for amide protons
considered to be significantly protected was set to 2, the
standard deviation of all subtracted values. Amide proton res-
onances associated with the FAT domain residues that were
protected from broadening in the FAT domain-LD2 complex
are localized to both helix 1, 4 and helix 2, 3 faces of the FAT
domain (Fig. 1B). These results support the ITC data and
provide further evidence for the two-site binding model of the
FAT domain-LD2 complex.
Observation of Intermolecular NOEs between the LD2 Pep-
tide and the FAT Domain—In order to observe intermolecular
NOEs between protein and ligand, an isotope-labeled, isotope-
filtered NOESY experiment was implemented. This technique
makes use of 13C and/or 15N labeling in one of the binding
components, i.e. the FAT domain in this case while leaving its
binding partner unlabeled (i.e. LD2 peptide). However, no NOE
cross-peaks were observed due to exchange broadening of
resonances associated with the LD2 peptide in the FAT do-
main-LD2 complex, consistent with earlier observations (40).
To increase the sensitivity associated with detection of inter-
molecular NOEs, we collected a pair of three-dimensional si-
multaneous 13C/15N-edited NOESY spectra of a 13C/15N dou-
ble-labeled FAT domain/unlabeled LD2 peptide complex, with
and without F1 decoupling during acquisition. All intramolec-
ular NOE peaks from the labeled FAT domain should appear as
doublets in the spectrum without F1 decoupling due to 1JNH or
1JCH coupling, whereas intermolecular NOE peaks involving
protons from unlabeled peptide appear as singlets in both spec-
tra (72). Comparison of coupled and decoupled 15N-edited spec-
tra revealed 10 intermolecular cross-peaks. Although the re-
sulting information could not be applied as NOE constraints
during structure calculations due to the inability to assign
exchange broadened peaks associated with the LD2 peptide in
the complex, we have been able to clearly prove the existence of
two LD2 peptide-binding sites on the FAT domain based on the
TABLE I
Thermodynamic parameters of the interaction between FAT variants or Pyk2 and LD2 peptide
Helix 1,4 site Helix 2,3 site
Kd H TS Kd H TS
M kcal/mol M kcal/mol
Wild type FAT 9.0  0.5 7.2  0.2 0.3  0.2 11.5  0.5 1.1  0.2 7.8  0.2
I937A 13.6  4.9 0.3  0.1 6.9  0.3
E949A/K956A/R963A 4.4  0.3 5.5  0.2 1.8  0.2
Pyk2 45  4 10  1 4  1 21  1 0.3  0.4 6.7  0.4
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available FAT domain assignments using this data. Two planes
taken from each of three-dimensional simultaneous 13C/15N
edited NOESY spectra, with or without F1 decoupling, are
shown in Fig. 1C. Peaks in the boxes that remain as singlets in
the coupled spectra are NOE peaks between the labeled protein
and the unlabeled peptide. In contrast, those peaks appearing
as doublets in the coupled spectra are NOE peaks within the
labeled FAT domain (72). According to our FAT domain assign-
ments, the boxed peaks correspond to close contacts between
the amide protons of residue His-1026 in helix 4 and Lys-989 in
helix 3 and the LD2 peptides. These two residues (His-1026
and Lys-989) are on the opposite sides of the molecule, provid-
ing additional evidence for the presence of two peptide-binding
sites in the FAT domain.
Interactions between the FAT Domain and Full-length Pax-
illin, Both in Vitro and in Vivo—The results of the peptide-
binding experiments demonstrate that a synthetic peptide
mimicking the LD2 motif of paxillin can dock to two distinct
sites on the FAT domain. To explore the role of the two paxillin
docking sites in mediating interactions of FAK with paxillin,
mutants were expressed as GST-FAT domain fusion proteins,
and their capacity to associate with paxillin was examined in
vitro. Fusion proteins were immobilized on glutathione beads
and then incubated with CE cell lysates. Bound paxillin was
detected by Western blotting. As shown in Fig. 2A, paxillin
bound to the wild type FAT domain of FAK but very poorly
associated with GST alone. The E949A/K956A/R963A mutant
exhibited reduced binding to paxillin compared with wild type,
although the mutant still exhibited significant binding relative
to the GST control. The I937A mutant bound to paxillin similar
to the wild type protein. This was surprising, because the
I937A mutant completely abolished binding of the LD2 peptide
to the helix 1, 4 binding site. Two other mutants, H1026A/
K1033A and K1019A/H1026A/K1033A, that retained LD2 pep-
tide binding to the helix 1, 4 binding site, but with reduced
affinity, were also analyzed. Both mutants bound to paxillin
similar to wild type. However, mutation of the helix 1, 4 bind-
ing site (I937A) in combination with mutation of the helix 2, 3
binding site (E949A/K956A/R963A) was required to ablate pax-
illin binding activity of the GST-FAT domain, as demonstrated
with the E949A/K956A/R963A/I937A mutant.
To further explore the role of the two paxillin-binding sites of
the FAT domain in the interaction with paxillin in vivo, wild
type full-length FAK or FAK mutants were transiently ex-
pressed in 293 cells. FAK was immunoprecipitated and co-
immunoprecipitated paxillin was detected by Western blotting
(Fig. 2B). A small amount of paxillin was co-immunoprecipi-
tated with endogenous FAK. A dramatic increase in the
amount of associated paxillin was observed in cells expressing
exogenous wild type FAK, due to the elevated level of FAK
expression. The E949A/K956A/R963A mutant exhibited re-
duced binding to paxillin relative to wild type FAK, although
more paxillin was immunoprecipitated than with endogenous
FAK, demonstrating that the mutant retained some paxillin
binding activity. I937A exhibited a small reduction in binding
activity, but clearly associated with paxillin substantially bet-
ter than E949A/K956A/R963A. Again, mutation of both paxil-
lin-binding sites in the E949A/K956A/R963A/I937A mutant
virtually abolished paxillin binding. These results suggest that
the two paxillin docking sites of the FAT domain may not
contribute equally to binding full-length paxillin. Disruption of
the helix 2, 3 binding site results in a more dramatic reduction
in paxillin binding relative to disruption of the helix 1, 4 bind-
ing site. However, simultaneous disruption of both binding
sites is required to eliminate paxillin binding.
Overall Structure of the FAT Domain—Following well estab-
lished assignment procedures, 98.0% of the backbone reso-
nances and 94.6% of the side chain resonances were assigned
for the structured regions of the FAT domain (residues 920–
1053) bound to the LD2 peptide. We have solved the NMR
solution structure of the FAT domain in complex with the LD2
peptide at moderately high resolution. Twenty five of the 100
NMR-derived structures with the lowest energies and the
smallest numbers of violations against experimental restraints
in the structural calculation were selected for further analysis.
The quality of the NMR structures is evident in the statistics
shown in Table II. Approximately 92% of the residues from 920–
1053 appear in the most favored regions of a Ramachandran
plot. For backbone atoms of residues in the secondary struc-
tures, the average r.m.s.d. to the mean structure is 0.67  0.11
Å. For all heavy atoms of residues 924–1050, the average
r.m.s.d. is 0.85  0.16 Å. The FAT domain is organized into a
“right-turn” four-helix bundle (Fig. 3). The helices are rela-
tively straight with different lengths: helix 1 is the shortest,
whereas helix 4 is the longest among the four helices. All the
helices are nearly parallel except helix 4. The helical axis of
helix 4 is about 10° from the elongated axis of the helix bundle
(Fig. 3, A and B), which is different from the available struc-
tures of either the free FAT domain or the FAT domain bound
to a shorter LD2 peptide (Fig. 3D and Table III). Notably, the
helix bundle has a well defined hydrophobic core shown by the
ordered green side chains in Fig. 3A. The helix bundle is likely
stabilized by extensive hydrophobic interactions among these
residues from all four helices. In fact, a large number of inter-
helical NOEs were observed not only between neighboring hel-
ices (helix 1 to helix 2 and helix 3 to helix 4) but also between
diagonal helices (helix 1 to helix 3 and helix 2 to helix 4). The
hydrophobic core of the helix bundle is indeed highly conserved
across species (39). However, the hydrophobic core is inter-
FIG. 2. Association of FAK mutants with full-length paxillin in
vitro and in vivo. A, CE lysate (500 g) was precleared with 25 g of
GST and then incubated with 6 g of GST (lane 2) or GST-FAT domain
constructs: wild type (WT) (lane 3), E949A/K956A/R963A (lane 4),
H1026A/K1033A (lane 5), I937A (lane 6), E949A/K956A/R963A/I937A
(lane 7), or K1019A/H1026A/K1033A (lane 8). After washing, bound
proteins were eluted in Laemmli’s sample buffer, and bound paxillin
was detected by Western blotting (top panel). As a control, 40 g of
lysate was directly loaded (lane 1). Comparable amounts of each fusion
protein were used in the analysis, as determined by SDS-PAGE and
Coomassie Blue staining (bottom panel). B, wild type FAK (lanes 2 and
4), E949A/K956A/R963A (lane 5), I937A (lane 6) or E949A/K956A/
R963A/I937A (lane 7) were transiently expressed in 293 cells. Control,
mock-transfected cells (lane 3), and FAK-expressing cells were lysed
and FAK immunoprecipitated (IP). Bound paxillin was detected by
Western blotting (top panel). As a control for nonspecific paxillin bind-
ing, protein A Sepharose alone was used as a negative co-immunopre-
cipitation control (lane 2). Lysate (25 g) was used as a control (lane 1).
The blot was stripped and reprobed for FAK to verify comparable
recovery of FAK variants (bottom panel).
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rupted by a cluster of four methionines shown in magenta,
which creates a distinct cavity at the top of the bundle (Fig. 3A).
Loop 1 connecting helix 1 and helix 2 and loop 3 connecting
helix 3 and 4 at the top of the bundle also have larger r.m.s.d.
values than the r.m.s.d. value of loop 2 at the bottom of the
bundle that connects helix 2 and 3 (Fig. 3C). Finally, as men-
tioned above, the distance between helix 1 and 4 is slightly
wider at the top than at the bottom of the bundle because of the
10° tilt angle of helix 4 with the rest of the helices. Taken
together, these structural features indicate the region around
the Met cluster of the helix bundle is less compact compared
with the hydrophobic core lying underneath. Interestingly,
three of four Tyr residues within FAT domain also appear at
the top of the bundle (Fig. 3A). Among them, Tyr-951 is buried
between loop 1 and 3, immediately above the Met cluster. Two
other conserved Tyr residues (Tyr-1008 and Tyr-1017) are sol-
vent-exposed. They are located at the two ends of loop 3, and
their aromatic side chains are arranged in a “ring-stacking”
position (Fig. 3A) and thus may play a role in stabilizing the top
end of the helix bundle.
Previous DALI data base searches revealed that despite the
lack of significant sequence similarity, the FAT domain is
structurally related to the vinculin tail domain (PDB access
code 1qkr), domains within -catenin (PDB access code 1h6g),
and apolipoprotein E3 (PDB access code 1nfn) (38–40). All of
these structures include a four-helix bundle with a simple
up-down-up-down right-handed topology (39). By inspection of
the PDB coordinates, we found that the vinculin tail domain
and a subset of apolipoproteins also have Met clusters within
the helix bundle. The helix bundles of both proteins are pro-
posed to “unfurl” to promote interaction with lipid substrates
using the exposed hydrophobic sites (73–75). NMR and x-ray
crystallographic studies of the free FAT domain revealed in-
trinsic flexibility of the helices in the helix bundle of the FAT
domain, especially helix 1, which is in intermediate exchange
on the NMR time scale and possesses enough conformational
flexibility to “domain exchange” with helix 1 of another FAT
domain molecule to form a domain swapped dimer in the crys-
talline state (38).2 The less compact cavity containing the me-
thionine cluster, in addition to a strained polyproline-rich
hinge region at the top of FAT domain bundle, may be respon-
sible for the capability of the FAT domain to “open up.” How-
ever, the plasticity of the helix bundle, particularly the helix 1,
is largely decreased by the association with the LD2 peptides in
our solution structure of the complex, as evidenced by perfectly
well defined conformation of all four helices, and by apparent
lack of the line broadening of NMR resonances seen in the
spectra of the free FAT domain (data not shown). In addition to
common structural and perhaps dynamic properties, functional
similarities between the FAT domain and the vinculin tail are
of particular interest, as both FAK and vinculin are localized to
focal adhesions through their FAT domain-like 4-helix bundle
tail domains. Like the FAT domain, the vinculin tail binds to
LD2 and LD4 motifs of paxillin. However, it is unclear whether
the FAT domain and the vinculin tail bind paxillin using a
similar binding epitope.
Surface Properties of the FAT Domain—The most noticeable
feature of the surface of the FAT domain is the presence of two
large hydrophobic patches on the opposite faces of the molecule
termed HP1 and HP2 (Fig. 4, A and B) by Hayashi et al. (39).
HP1 is located at the interface between helix 2 and 3, whereas
HP2 is located at the interface between helix 1 and 4. However,
comparison of recent structures of the FAT domain, both free
and LD2 bound, show two noticeable differences in the hydro-
phobic patches. 1) HP1 traverses much of the helix 2, 3 surface
from top to bottom in our solution structure of the FAT domain
bound by the LD2 peptide, in contrast to HP1 in the crystal
structure and our recent solution structure of the free FAT
domain (38, 39),2 where the HP1 patch resides in the center of
helix 2, 3 interface. This is presumably due to the subtle con-
formational changes of the helix 2 and 3. 2) The hydrophobic
area of HP2 becomes larger upon binding the LD2 peptide
because of the slight split between helix 1 and 4 and/or the
partial exposure of the Met cluster. From our thermodynamic
studies, it is very clear that the binding between the FAT
domain and the LD2 peptide involves large scale hydrophobic
interactions. This information, when combined with our para-
magnetic mapping experiments, indicates that HP1 and HP2
represent the binding sites for the hydrophobic faces of the LD2
peptide. Indeed HP2 and especially HP1 are two surfaces that
have a great deal of sequence conservation among FAT do-
mains (38, 39). The electrostatic surfaces shown in Fig. 4, C and
D, represent views illustrating the same surfaces as in Fig. 4,
A and B. Areas of positively charged residues are present at
positions indicated in Fig. 4, C and D, immediately adjacent to
the two hydrophobic patches, including conserved residues
Lys-934 in helix 1, Lys-956, Arg-963 in helix 2, Lys-1003 in
helix 3, and Lys-1019, His-1026, and Lys-1033 in helix 4. Con-
sidering the acidic nature of LD2 peptide and its strong pro-
pensity to form an amphipathic -helical conformation, the
conservation of these distinct electropositive spots and adjacent
large hydrophobic patches strongly suggest that the interfaces
between helix 1 and 4, and helix 2 and 3 are the binding sites
for the LD2 peptide. Analysis of the surface formed by helix 1
and 2 and the surface formed by helix 3 and 4 reveals different
TABLE II















Residues in most favored regions 91.9%
Residues in additional allowed
regions
5.3%
Residues in generally allowed
regions
1.9%
Residues in disallowed regions 0.8%
Average violations per structure
Distance restraints (
0.5 Å) 2.2
Dihedral angle restraints (
5o) 4.4
Mean r.m.s.d. from experimental
restraints
Distance (Å) 0.05  0.01
Dihedral angle (o) 1.39  0.20
Residual dipolar coupling (Hz) 0.96  0.17
Mean r.m.s.d. from idealized
geometry
Bonds (Å) 0.0049  0.0002
Angles (o) 0.72  0.02
Improper (o) 2.10  0.10
R.m.s.d. to the mean structure (Å)
All residues excluding the termini
(924–1050)
Backbone atoms 0.85  0.16
All heavy atoms 1.69  0.19
Secondary structures (926–941,
950–976, 983–1006, 1016–1048)
Backbone atoms 0.67  0.11
All heavy atoms 1.57  0.19
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properties than the surfaces containing HP1 and HP2: 1) the
absence of the large hydrophobic area; and 2) the presence of
dominantly electronegative patches in the center of the sur-
faces (Fig. 4, E and F). These distinct features suggest it is
impossible for the helix 1, 2 and helix 3, 4 surfaces to interact
with paxillin LD motifs in a similar fashion. However, it is
possible these two surfaces provide additional protein-protein
interaction sites for other FAT domain ligands, such as talin.
Our solution structure of the FAT domain in complex with the
LD2 peptide also explains the widespread chemical shift
changes shown in the 1H-15N HSQC spectra for virtually all
residues upon peptide binding. These changes were due to the
following: 1) the subtle conformational changes of helices that
were observed between the free and bound states of the FAT
domain, especially helix 4; and 2) the involvement of all four
helices in peptide binding, altering the chemical environments
experienced by almost all residues in the FAT domain.
Structure of FAT Domain Bound by LD2 Peptide Accounts for
Available Mutagenesis Data—Two studies have characterized
several mutations in the FAT domain in an effort to better
understand FAT domain function (23, 24), particularly the
relationship between paxillin binding and focal adhesion tar-
geting. In the first study (23), point mutations were introduced
into either helix 1 or 4 of the FAT domain within regions of
sequence homology with vinculin (23). However, the majority of
mutants that abrogated paxillin binding are associated with
residues involved in helix packing and are likely to result in
structural alterations of the FAT domain (V928G, L931R,
V935A, L1034S, L1035A, V1037D corresponding to V929G,
L932R, V936A, L1035S, L1036A, V1038D in the avian FAT
domain). The majority of mutations that had no effect on pax-
illin binding or focal adhesion targeting involved solvent-ex-
posed residues on either the helix 1, 2 face (K923E correspond-
ing to K924E in the avian FAT domain), helix 1, 4 face
FIG. 3. Solution structure of FAT
bound by LD2 peptide (133–159). A,
ensemble of 25 structures (residues 920–
1053). Side chain heavy atoms of well de-
fined residues in the hydrophobic core of
the helical bundle are colored green. Side
chain heavy atoms of four Tyr residues
are highlighted in red, with the residue
numbers labeled. The Met cluster is
shown in magenta. B, ribbon plot of the
backbone structure of FAT in complex
with LD2 peptide in an orientation simi-
lar to A. Representative model 3 is drawn
with four -helices colored. C, the 25 so-
lution structures of FAT are represented
with a backbone tube of thickness propor-
tional to the backbone r.m.s.d., again in
an orientation similar to A. Four -helices
are colored in the same manner as in B.
Loops and termini are colored gray. D,
superposition of 25 NMR models of avian
FAT (1qvx, blue) bound by LD2 peptide
with the following structures: represent-
ative avian FAT NMR structure (1ktm,
model 1, red) in complex with a similar
LD2 peptide; representative free avian
FAT NMR structure2 (1pv3, model 1,
cyan); free mouse FAT x-ray structure
(1k40, green); and free human FAT x-ray
structure (1k05, yellow). The backbone at-
oms (N, C, C) of FAT residues 926–941,
950–976, 983–1006, and 1016–1047 were
superimposed on the backbone atoms of
mouse or human FAT residues 925–940,
949–975, 982–1005, and 1015–1046. The
view in D is a rotation of the view of A,
nearly 180° about the long axis of helical
bundle. All figures were generated by
MolMol (76).
TABLE III
Comparison of structure of FAT models
Comparison of structure of FAT models was based on pairwise superposition of backbone carbon and nitrogen atoms of residues in secondary
structure (926–941, 950–976, 983–1006, and 1016–1047). Fitting was performed using the McLachlan algorithm (41) as implemented in the
program ProFit (/www.bioinf.org.uk/software/profit).







FAT bound by LD2, NMR, 1qvx 2.40  0.08 2.54  0.07 2.04  0.08 1.83  0.06
FAT bound by LD2, NMR, 1ktm 2.12  0.07 1.47  0.06 1.36  0.04
Free FAT, NMR, 1pv3a 2.12  0.07 1.64 1.91
Free FAT, X-ray, 1k40 1.47  0.06 1.64 0.94
a Using model 1, judged most representative by its authors.
b A chain of 1k05.
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(T929S/R, K933E, D1036H, L1043R corresponding to T930S/R,
K934E, D1037H, L1044R in the avian FAT domain), or the
helix 3, 4 face (N1033D, Q1040E/G/K corresponding to
N1034D, Q1041E/G/K in the avian FAT domain). Two of the
mutants that abrogated paxillin binding to the FAT domain are
solvent-exposed residues located near the end of helix 4
(D1039A, R1042G corresponding to D1040A, R1043G in the
avian FAT domain), which is distant from the proposed helix 1,
4 binding site. Based upon either our models of LD motif-FAT
domain interactions or that reported by Liu et al. (40), it is
unclear how these mutations perturb paxillin binding.
In the second study, a set of avian FAT domain mutants
targeted to helices 2, 3, and 4 was engineered (24). Two mu-
tants (L995A/L998A and L1028A/L1035A) abrogated both pax-
illin binding as well as focal adhesion targeting. Both mutants,
however, targeted residues located in the hydrophobic core of
the FAT domain and may perturb the structure of the FAT
domain, which could account for disruption of paxillin binding
and resulting FAK signaling deficiencies. The E985A/K989A
mutant retains paxillin binding and focal adhesion targeting
properties similar to those of the wild type FAT domain. Glu-
985 and Lys-989 are not in the immediate vicinity of the pro-
posed binding site; therefore, this mutant would be predicted to
have a minimal effect on paxillin binding. Two additional mu-
tants were made that reduced paxillin binding and still tar-
geted FAK to focal adhesions. The E949A/K956A/R963A mu-
tant removes significant positive charge from the hydrophobic
patch of the helix 2, 3 paxillin-binding site, whereas the
H1026A/K1033A mutant similarly removes positive charge
near the hydrophobic patch of the helix 1, 4 binding site. As will
be discussed below, these electropositive residues are impor-
tant for the FAT-LD2 interaction.
Modeling of FAT-LD2 Complex Using Mutagenesis Data by
HADDOCK Program—NMR efforts failed to experimentally
extract intermolecular NOEs between the FAT domain and the
LD2 peptide in the FAT domain-LD2 complex, or intramolecu-
lar LD2 peptide NOEs in the FAT domain-LD2 complex for
structure calculations, in both a previous study (40) and our
present NMR study. Consistent with these observations, we
have observed that resonances associated with the LD2 peptide
are in intermediate exchange on the NMR time scale and are
consequently broadened beyond detection in the FAT domain-
LD2 complex. Hayashi et al. first generated a model for these
interactions by manually docking the LD2 peptide onto their
free FAT domain crystal structure followed by energy minimi-
zation (39). In the previous NMR study, Liu et al. (40) were able
to extract a few intermolecular distance restraints between the
FAT domain and the LD2 peptide by site-directed paramag-
netic spin labeling of the peptide, and then used these re-
straints to model their structure of the free LD2 peptide onto
the solution structure of the FAT domain in the LD2-bound
state (40). Although Hayashi et al. (39) and Liu et al. (40) both
modeled the LD2 peptide in a helical conformation when it
binds to the FAT domain, their resultant models are funda-
mentally different as follows. 1) Hayashi et al. (39) identified
two surfaces containing either HP1 or HP2 as the LD2-binding
sites, whereas Liu et al. (40) only found one LD2-binding site at
the interface of helix 1 and 4, corresponding to the surface
containing HP2 in the model by Hayashi. 2) The LD2 peptide
docked at the interface of helix 1 and 4 in these two models are
in opposite orientations. There is no question that the manual
modeling approach is subjective in nature. However, the para-
magnetic spin-labeling technique is also not error-free. Extra
caution has to be taken during the analysis of line broadening
data involving the spin-labeling technique. 1) It is very possible
that the Cys mutation of the LD2 peptide residues followed by
chemical modification will alter the affinity of the LD2 peptide
for the FAT domain. 2) The presence of excessive concentra-
tions of spin-labeled peptides in solution may lead to nonspe-
cific binding interactions with the protein, therefore a very
careful “background” calibration is necessary.
A recently introduced approach, using the HADDOCK pro-
gram (67), provided us with an alternative method to dock the
LD2 peptide onto FAT and has been proven to be very success-
ful in the present study. By using this approach, we introduced
available mutagenesis data as ambiguous interaction re-
straints to drive the docking process. An ambiguous interaction
restraint is defined as an ambiguous distance between all res-
idues shown to be involved in the interaction. Another advan-
tage of the application of HADDOCK over the two techniques
described above is that it accommodates conformational rear-
rangements during the docking process by allowing side chain
rearrangements, which is crucial for the FAT domain-LD2
complex. The final five models with the lowest intermolecular
energy after the docking process have very low backbone
r.m.s.d. for both the helix 1, 4 and helix 2, 3 sites: 0.65  0.12
Å for LD2 peptide docked onto helix 1, 4 site with an intermo-
lecular energy of 220  12 kcalmol1, and 0.43  0.07 Å for
LD2 peptide docked onto helix 2, 3 site with an intermolecular
energy of 232  10 kcalmol1. Fig. 5 represents a view of the
helix 1, 4 (Fig. 5A) and helix 2, 3 site (Fig. 5B). The orientation
of the LD2 peptide at the helix 1, 4 binding site is similar to
that reported previously by Liu et al. (40). Two general simi-
FIG. 4. Surface of solution structure of FAT bound to LD2.
Surface of helix 1,4 (A) and 2,3 (B) are color-coded for hydropathy and
charge (green, hydrophobic; white, hydrophilic; red, Asp and Glu; blue,
Lys, Arg and His). C–F are electrostatic potential surfaces of FAT bound
to LD2, colored from 10 (red) to 10 (blue) kT e1. The surfaces in C
and D are the same as those in A and B. The views in E and F involve
a 90° rotation, relative to C and D, respectively, about the long axis of
the helix bundle. They represent surfaces of helix 1,2 (E) and helix 3,4
(F). These molecular surfaces, derived from representative NMR model
3, were generated using GRASP (77).
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larities between the helix 1, 4 and helix 2, 3 binding sites are as
follows. 1) The critical Asp-146 residue on the LD2 peptide
makes salt bridges to the conserved basic residues of the FAT
domain (His-1026 and Lys-1033 within the helix 1, 4 site;
Arg-963 and/or Lys-956 within the helix 2, 3 site) in close
proximity to the hydrophobic patches HP1 and HP2. 2) The
hydrophobic side chains from the LD2 peptide, especially the
leucine residues shown in green, fit extremely well into the
hydrophobic grooves of HP1 and HP2. Our docking models
suggest that the structured regions of the LD2 peptide bind to
the helix 1, 4 and helix 2, 3 sites in a similar manner. However,
the ITC results clearly indicate the thermodynamic basis gov-
erning the protein-peptide interactions are fundamentally dif-
ferent despite the similar affinities; the binding between helix
1, 4 site and the LD2 peptide is mainly enthalpically driven,
whereas the binding between helix 2, 3 site and the LD2 pep-
tide is essentially entropically driven (Table I). We postulate,
based on these results, that the relatively flexible N- and/or
C-terminal residues may also interact with the FAT domain. In
fact, 2–3-fold decrease in the affinity was observed for both
FAT-binding sites when a shorter LD2 peptide lacking the
highly conserved N-terminal 8 residues was used during the
ITC titrations (data not shown). One important difference be-
tween our current model of the FAT domain-LD2 complex and
that reported by Liu et al. (40), besides the presence of two
LD2-binding sites versus one binding site, is that there appears
to be a slight split at the top of the helix bundle, between helix
1 and 4 in our structure in the LD2 peptide-bound state. Dis-
crepancies between these structures may be due to the follow-
ing differences in the complexes under investigation. 1) Differ-
ent LD2 peptide sequences were employed (LD2 residues 139–
162 by Liu et al. (40) versus 133–159 in this study). 2) Different
protein/peptide molar ratios were used for the NMR studies of
the complex (1:5 by Liu et al. (40) versus 1:8 in this study).
However, our ITC and paramagnetic relaxation broadening
results acquired on a shorter LD2 peptide lacking 8 N-terminal
residues (LD2 residues 141–159) indicated a similar mode of
binding to the FAT domain, albeit with a modest decrease in
the affinity for each of the two binding sites (data not shown).
Hence, the underlying reasons for the differences between
these two independent NMR studies are unclear.
Biological Implications for Multiple Paxillin LD Motif-bind-
ing Sites on the FAT Domain—FAK and paxillin are focal adhe-
sion-associated, phosphotyrosine-containing proteins that physi-
cally interact (34). The binding of FAK to paxillin is mediated by
LD2 and LD4 motifs within the N-terminal half of paxillin (34,
36). Interestingly, a larger fragment of paxillin encompassing
both LD2 and LD4 motifs binds 5–10-fold more strongly than
each individual LD motif peptide, and the critical Asp mutations
in both LD motifs of the larger fragment are required to dramat-
ically impair FAK binding in vitro (34). The reason for two FAK-
binding sites on paxillin and two paxillin-binding sites on FAK is
unclear. Multiple docking sites may simply be a mechanism to
increase the avidity of the interaction. Alternatively, multiple
docking sites may allow the assembly of higher order complexes
containing a number of FAK and paxillin molecules. Formation
of such complexes may function in the regulation of FAK or
paxillin signaling. In addition, the functional significance of
two binding sites is unclear, i.e. is paxillin bound to HP1
functionally redundant with paxillin bound to HP2?
The role of distinct paxillin-binding sites in vivo is open to
speculation. Whereas previous mutational analyses, albeit
with most of the mutations now predicted to perturb structure,
demonstrate that paxillin binding is dispensable for localiza-
tion of FAK, disruption of paxillin binding may have more
subtle effects upon localization. Analysis of a paxillin mutant
defective for FAK binding reveals reduced levels of phosphoty-
rosine relative to wild type paxillin (34). These results sug-
gested that paxillin must bind FAK for maximal paxillin phos-
phorylation in response to cell adhesion. Hence, FAK may
function to direct tyrosine phosphorylation of paxillin. Several
analyses have also suggested that disruption of paxillin func-
tion may impair tyrosine phosphorylation of FAK and Pyk2 (28,
31). These findings suggest that paxillin association could also
potentially regulate FAK signaling. Given the additional com-
plexity of the FAK-paxillin interaction, i.e. presence of multiple
binding sites, the question of functional redundancy between
specific FAK-paxillin complexes must again be raised. Al-
though these intriguing questions remain to be addressed, the
mutants developed in this study will be invaluable in further
studies designed to further explore these issues.
Accession Numbers—The resonance assignments have been
deposited in the BioMagResBank (http://www.bmrb.wisc.edu)
under BMRB accession number 5924. The ensemble of 25 NMR
models has been deposited under PDB accession code 1qvx.
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FIG. 5. NMR-derived models of the FAT-paxillin complex using the HADDOCK program. Proposed model of LD2 peptide (gold) in helical
conformation docked onto the surface of helix 1, 4 (A) and helix 2, 3 (B). Electrostatic potential surfaces of FAT were generated by MolMol (76) using
default parameters. The side chain of the critical LD2 residue, Asp-146, is shown as a ball-and-stick representation. Side chains of seven LD2
leucine residues are colored in green. FAT residues identified as active residues during the docking process, as described in the “Experimental
Procedures,” are indicated.
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Addendum—After we submitted this paper, the crystal structures of
the human FAT domain in complex with a shorter paxillin LD2 or LD4
peptide were reported (Hoellerer, M. K., Noble, M. E., Labesse, G.,
Campbell, I. D., Werner, J. M., and Arold, S. T. (2003) Structure 11,
1207–1217). This paper confirms the presence of two LD-binding sites
within the FAT domain, and the structures are in good agreement with
our models demonstrating the utility of the HADDOCK/NMR approach
for modeling FAT-LD2 binding interactions.
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